Roberto Contieri, Urologist at the National Cancer Institute G. Pascale Foundation, Naples, Italy, shared a post on LinkedIn about a paper he co-authored with colleagues published in the International Urology and Nephrology:
“First of 2026!
Should we really administer MMC maintenance in patients with intermediate-risk Ta NMIBC, and for how long?
While EAU guidelines recommend adjuvant intravesical chemotherapy, the optimal duration of MMC maintenance remains unknown.
To address this clinically relevant gap, we conducted a multicenter study including 292 patients with EAU 2021 intermediate-risk Ta NMIBC.
Importantly, we applied a 12-month landmark analysis to minimize immortal time bias and allow a fair comparison between different maintenance strategies.
Key findings
- MMC maintenance was associated with a significantly improved RFS compared with no maintenance (2-year RFS: 78% vs 55%).
- Using CART analysis, >6 monthly MMC instillations emerged as the optimal cutoff.
- Long-term MMC maintenance (>6 instillations) significantly reduced recurrence risk compared with both no maintenance and short-term (≤6) maintenance.
Take-home message
MMC maintenance clearly matters in intermediate-risk Ta NMIBC, in line with other recent evidence.
At least 6 months of MMC maintenance appears necessary to achieve a meaningful reduction in recurrence risk.”
Title: Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis
Authors: Roberto Contieri, Letizia Maria Ippolita Jannello, Mihai Dorin Vartolomei, Beat Roth, Roberto Bianchi, Giuseppe Fallara, Marco Tozzi, Martina Maggi, Francesco Chierigo, Francesco Pellegrino, Ludovica Cella, Alessandro Uleri, Luigi Da Pozzo, Francesco Claps, Achille Aveta, Gianluca Spena, Enrico Checcucci, Cecilia Gatti, Pierluigi Bove, Francesca Vedovo, Gian Maria Busetto, Ugo Falagario, Riccardo Mastroianni, Alessandro Tedde, Massimo Madonia, Pasquale Di Tonno, Giuseppe Lucarelli, Saverio Forte, Giorgio Ivan Russo, Fabrizio Verweij, Marco Racioppi, Francesco Pio Bizzarri, Marco Borghesi, Marco Rinaldi, Fabio Zattoni, Luca Boeri, Elisa De Lorenzis, Andrea Conti, Maria Angela Cerruto, Felice Crocetto, Giuseppe Simone, Savino Mauro Di Stasi, Cosimo De Nunzio, Luca Carmignani, Giovanni Liguori, Angelo Porreca, Biagio Barone, Emanuele Montanari, Albo Giancarlo, Alessandro Antonelli, Alessandro Veccia, Fabrizio Dal Moro, Giuseppe Carrieri, Luigi Cormio, Carlo Terrone, Francesco Porpiglia, Sisto PerdonĂ , Bernardo Rocco, Rodolfo Hurle, Michele Catellani, Matteo Ferro
You can read the Full Article in the International Urology and Nephrology.
More posts featuring Roberto Contieri.
